Latisha Houze-Reed
Family · Beaumont, MSNPI 1922402247
Payments from drug & device makers
Across 112 payments — averaging $17.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$696
- AstraZeneca$305
- Johnson & Johnson$128
- Jazz Pharmaceuticals Inc.$111
- Mallinckrodt Hospital Products Inc.$107
- Actelion Pharmaceuticals US, Inc.$107
- plus $556 from 13 others
What the payments were for
- Food & beverage$2,009100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 49 | $696 |
| AstraZeneca | 12 | $305 |
| Johnson & Johnson | 9 | $128 |
| Jazz Pharmaceuticals Inc. | 1 | $111 |
| Mallinckrodt Hospital Products Inc. | 5 | $107 |
| Actelion Pharmaceuticals US, Inc. | 6 | $107 |
| Boehringer Ingelheim | 6 | $95 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $93 |
| AbbVie | 4 | $72 |
| Novo Nordisk | 1 | $57 |
| Sanofi | 3 | $49 |
| Merck | 2 | $39 |
| Mylan Specialty L.p. | 2 | $37 |
| Bayer | 2 | $29 |
| Exact Sciences | 1 | $23 |
| Xeris Pharmaceuticals, Inc. | 1 | $17 |
| Boston Scientific | 1 | $17 |
| Inari Medical, Inc. | 1 | $16 |
| Gilead | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,009 in reported general payments places this provider in the 80th percentile of 3,007 family providers in Mississippi.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 46 | $46,074 |
| OzempicSemaglutide | 24 | $26,648 |
| EliquisApixaban | 20 | $22,575 |
| XareltoRivaroxaban | 22 | $15,623 |
| LinzessLinaclotide | 11 | $11,542 |
| TradjentaLinagliptin | 11 | $11,503 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 22 | $4,436 |
| Esomeprazole Magnesium | 27 | $2,461 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 57 | $2,320 |
| Levemir FlexpenInsulin Detemir | 15 | $1,928 |
| Metoprolol Succinate | 73 | $1,194 |
| Atorvastatin Calcium | 152 | $1,078 |
| Amlodipine Besylate | 231 | $994 |
| Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide | 13 | $957 |
| Gabapentin | 113 | $956 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $57 | $26,64824 claims |
| Johnson & JohnsonXarelto | $128 | $15,62322 claims |
| AbbVieLinzess | $72 | $11,54211 claims |
| Boehringer IngelheimTradjenta | $95 | $11,50311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,007 family providers in Mississippi.
Other family in Beaumont
- Cinda PerrymanFayette$888K
- Dodie McGeeRaymond$772K
- Gina BurgeJackson$237K
- Christy DavisJackson$208K
- Maranda EversollFlowood$197K
- Dana DelaskiJackson$158K
- Kristin CarrollJackson$158K
- Shannon FryeryOxford$127K
- Nativel CollinsMantachie$73K
- Ashley CocilovaFlowood$72K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.